CoChat

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Introduction Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC.Methods Patients with resectable stage IB-IIIA nonsquamous NSCLC were treated with bevacizumab followed by imaging 2 weeks later to assess single-agent effect. After this they received two cycles of bevacizumab with four cycles of cisplatin and docetaxel followed by surgical resection. Resected patients were eligible for adjuvant bevacizumab. The primary endpoint was the rate of pathological downstaging (decrease from pretreatment clinical stage to post-treatment pathological stage). Secondary endpoints included overall survival, safety, and radiologic response.Results Fifty patients were enrolled. Thirty-four (68%) were clinical stage IIIA. All three doses of neoadjuvant bevacizumab were delivered to 40 of 50 patients. Six patients (12%) discontinued because of bevacizumab-related adverse events. The rate of downstaging (38%), response to chemotherapy (45%), and perioperative complications (12%) were comparable with historical data. No partial responses were observed to single-agent bevacizumab, but 18% of the patients developed new intratumoral cavitation, with a trend toward improved pathologic response (57% versus 21%; p = 0.07). A major pathologic response (≥90% treatment effect) was associated with survival at 3 years (100% versus 49%; p = 0.01). No patients with KRAS-mutant NSCLC (0 of 10) had a pathologic response as compared with 11 of 31 with wild-type KRAS.Conclusion Although preoperative bevacizumab plus chemotherapy was feasible, it did not improve downstaging in unselected patients. New cavitation after single-agent bevacizumab is a potential biomarker. Alternative strategies are needed for KRAS-mutant tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e31829923ec

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 2

  1. Felip, 2009, Surgery Alone, or Surgery Followed by Adjuvant Paclitaxel/Carboplatin (PC) or Preoperative PC Followed by Surgery, in Early Stage Non-Small Cell Lung Cancer: Results of the Multicenter, Randomized, Phase III NATCH Trial, J Clin Oncol, 27, CRA7500
  2. Pataer, 2012, Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy, J Thorac Oncol, 7, 825, 10.1097/jto.0b013e318247504a · DOI · Paper page

Cited by

See all 122

Metadata

Authors
Chaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., Price, K. A. R., Azzoli, C. G., Fury, M. G., Riely, G. J., Krug, L. M., Downey, R. J., Bains, M. S., Sima, C. S., Rizk, N., Travis, W. D., & Rizvi, N. A.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Rizvi, Naiyer A.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2013-08
Volume
8
Issue
8
Pages
1084-1090
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2019204011
Cited by
122
References
21
Citations by year
2026: 2 · 2025: 3 · 2024: 7 · 2023: 15 · 2022: 17 · 2021: 25 · 2020: 16 · 2019: 3 · 2018: 10 · 2017: 4 · 2016: 7 · 2015: 5 · 2014: 4 · 2013: 4
FWCI
5.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Thoracic Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
bevacizumab, non-small cell lung cancer, non-squamous non-small cell lung cancer, neoadjuvant chemotherapy, cisplatin, docetaxel, pathological downstaging, KRAS mutation, surgical resection, overall survival, biomarkers
MeSH terms
Bevacizumab, Filgrastim, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Polyethylene Glycols, Recombinant Proteins, Tomography, X-Ray Computed, Granulocyte Colony-Stimulating Factor, Neoadjuvant Therapy, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers. https://app.cochat.ai/papers/10.1097/jto.0b013e31829923ec
The paper
Chaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., Price, K. A. R., Azzoli, C. G., Fury, M. G., Riely, G. J., Krug, L. M., Downey, R. J., Bains, M. S., Sima, C. S., Rizk, N., Travis, W. D., & Rizvi, N. A. (2013). Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0b013e31829923ec

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.